Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 910-916

  Harper, M E ^a   Glynne Jones, E ^a   Goddard, L ^a   Thurston, V J ^a   Griffiths, K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Chromogranin A; Neuroendocrine cell; Prostatic tumour; Transforming growth factor alpha; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; CHROMOGRANIN A; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER GRADING; CARCINOMA CELL; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEUROSECRETORY CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

EID: 0029774076     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.456     Document Type: Article

References (59)

1. ABDUL M, ANEZINIS PE, LOGOTHETIS CJ AND HOOSEIN NM. (1994). Growth inhibition of human prostate cell lines by serotonin antagonists. Anticancer Res., 14, 1215-1220.
2. ABRAHAMSSON PA, WADSTROM LB, ALUMETS J, FALKMER S AND GRIMELIUS L. (1987). Peptide hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol. Res. Prac., 182, 298-307.
3. ADLAKHA H AND BOSTWICK DG. (1994). Paneth cell like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum. Pathol., 25, 135-139.
4. ANANDAPPA SY, WINSTANLEY JH, LEINSTER S, GREEN B, RUDLAND PS AND BARRACLOUGH R. (1994). Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br. J. Cancer, 69, 772-776.
5. APRIKIAN AG, CORDON-CARDO C, FAIR WR AND REUTER VE. (1993). Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer, 71, 3952-3965.
6. BANG YJ, PIRNIA F, FANG WG, KANG WK, SARTO O, WHITESELL L, HA MJ, TSOKOS M, SHEAHAN MD AND NGUYEN P. (1994). Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc. Natl Acad. Sci. USA, 91, 5330-5534.
7. BEAUCHAMP RD, COFFEY RJ, LYONS RM, PERKETT EA, TOWNSEND CM AND MOSES HL. (1991). Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res., 51, 5253-5260.
8. BEBOK Z, MARKUS B AND NEMETH P. (1994). Prognostic relevance of transforming growth factor alpha (TGF alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry. Breast Cancer Res. Treat., 29, 229-235.
9. BENHARROCH D AND BIRNBAUM D. (1990). Biology of the fibroblast growth factor gene family. Israel J. Med. Sci., 26, 212-219.
10. BONKHOFF H, WERNERT N, DHOM G AND REMBERGER K. (1991). Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate, 19, 91-98.
11. BOSARI S, LEE AK, DELELLIS RA, WILEY BD, HEATLEY GJ AND SILVERMAN ML. (1992). Microvessel quantitation and prognosis in invasive breast carcinoma. Hum. Pathol., 23, 755-761.
12. BROWN LF, BERSE B, JACKMAN RW, TOGNAZZI K, GUIDI AJ, DVORAK HF, SENGER DR, CONNOLLY JL AND SCHNITT SJ. (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26, 86-91.
13. CHAUDHRY A, PAPANICOLAOU V, OBERG K, HELDIN CH AND FUNA K. (1992). Expression of platelet derived growth factor and its receptor in neuroendocrine tumors of the digestive system. Cancer Res., 52, 1006-1012.
14. CHAUDHRY A, FUNA K AND OBERG K. (1993). Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol., 32, 107-114.
15. CHING KZ, RAMSEY E, PETTIGREW N, D'CUNHA R, JASON M AND DODD JG. (1993). Expression of mRNA for epidermal growth factor, transforming growth factor alpha and their receptor in human prostate tissue and cell lines. Mol. Cell Biochem., 126, 151-158.
16. COHEN RJ, GLEZERSON G, HAFFEJEE Z AND AFRIKA D. (1990). Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br. J. Urol., 66, 405-410.
17. COHEN RJ, GLEZERSON G AND HAFFEJEE Z. (1991). Neuro-endocrine cells - A new prognostic marker in prostatic cancer. Br. J. Urol., 68, 258-262.
18. COHEN RJ, GLEZERSON G AND HAFFEJEE Z. (1992). Prostate specific antigen and prostate specific acid phosphatase in neuroendocrine cells of prostatic cancer. Arch. Pathol. Lab. Med., 116, 65-66.
19. DI SANT'AGNESE PA. (1992). Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol., 23, 287-296.
20. DI SANT'AGNESE PA AND DE MESEY JENSEN KL. (1987). Neuroendocrine differentiation in prostatic carcinoma. Hum. Pathol., 18, 849-856.
21. FOLKMAN J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Iust., 82, 4-6.
22. FOLKMAN J AND KLAGSBRUN M. (1987). Angiogenic factors. Science, 235, 442-447.
23. GLYNNE-JONFS E, HARPER ME, GODDARD L, EATON CL, MATTHEWS PN AND GRIFFITHS K. (1994). Transforming growth factor beta expression in benign and malignant prostatic tumors. Prostate, 25, 210-218.
24. HALL MC, TRONCOSO P, POLLACK A, ZHAU HY, ZAGARS GK, CHUNG LW AND VON ESCHENBACH AC. (1994). Significance of tumor angiogenesis in clinically localised prostate carcinoma treated with external beam radiotherapy. Urology, 44, 869-875.
25. HARPER ME, GODDARD L, GLYNNE-JONES E, WILSON DW, PRICE THOMAS M, PEELING WB AND GRIFFITHS K. (1993). An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. Prostate, 23, 9-24.
26. HARPER ME, GODDARD L, GLYNNE JONES E, PEEEING WB AND GRIFFITHS K. (1995). Epidermal growth factor expression by northern analysis and immunocytochemistry in benign and malignant prostatic tumours. Eur. J. Cancer, 31A, 1492-1497.
27. HORAK ER, LEEK R, KLENK N, LEJEUNE S, SMITH K, STUART N, GREENALL M AND HARRIS AL. (1992). Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies as an indicator of node metastasis and survival in breast cancer. Lancet, 340, 1120-1124.
28. ITOT, KITAMURA H, NAKAMURA H, KAMEDA Y AND KANISAWA M. (1993). A comparative study of vascular proliferation in brain metastasis of lung carcinomas. Virchows Archiv A, 423, 13-17.
29. KIM KJ, LI B, WINER J, ARMANINI M, GILLETT N, PHILLIPS HS AND FERRARA N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841-844.
30. KONDO S, ASANO M AND SUZUKI H. (1993). Significance of vascular endothelial growth factor/permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem. Biophys. Res. Commun., 194, 1234-1241.
31. KRIJNEN JLM, JANSSEN PJA, RUIZEVELD DE WINTER JA, VAN KRIMPEN H, SCHOEDER FH AND VAN DER KWAST TH. (1993). Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry, 100, 393-398.
32. LIU XH, WILEY HS AND MEIKLE AW. (1993). Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J. Clin. Endocrinol. Metab., 77, 1472-1478.
33. MACCHIARINI P, FONTANINI G, HARDIN MJ, SQUARTINI F AND ANGELETTI CA. (1992). Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet, 340, 145-146.
34. MATTERN J, KOOMAGI R AND VOLM M. (1996). Association of vascular endothelial growth factor expression with intratumoral microvascular density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer, 73, 931-934.
35. MOSTOFI FK, SESTERHOLM I AND SOBIN LH. (1980). Histological typing of prostatic tumours. International Histological Classification of Tumours, No. 22. World Health Organization: Geneva.
36. NEUFELD G, TESSLER S, GITAY-GOREN H, COHEN T AND LEVI BZ. (1994). Vascular endothelial growth factor and its receptors. Prog. Growth Factor Res., 5, 89-97.
37. NILSSON O, WANGBERG B, THEODORSSON E, SKOTTNER A AND AHLMAN H. (1992). Presence of IGF-1 in human midgut carcinoid tumours an autocrine regulator of carcinoid tumour growth? Int. J. Cancer, 51, 195-203.
38. NILSSON O, WANGBERG B, KOLBY E, SCHULTZ GS AND AHLMAN H. (1995). Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int. J. Cancer, 60, 645-651.
39. O'BRIEN T, CRANSTON D, FUGGLE S, BICKNELL R AND HARRIS AL. (1995). Different angiogenic pathways characterise superficial and invasive bladder cancer. Cancer Res., 55, 510-513.
40. ONO M, OKAMURA K, NAKAYAMA Y, TOMITA M, SATO Y, KOMATSU Y AND KUWANO M. (1992). Induction of human microvascular endothelial tubular morphogenesis by human keratinocytes: involvement of transforming growth factor-alpha. Biochem. Biophys. Res. Commun., 189, 601-609.
41. PLATE KH, BREIER G AND RISAU W. (1994). Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol., 4, 207-218.
42. REINARTZ JJ, GEORGE E, LINDGREN BR AND NIEHANS GA. (1994). Expression of p53, transforming growth factor alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum. Pathol., 25, 1075-1083.
43. SAUTER ER, COIA LR, EISKNBERG BL AND HANKS GE. (1995). Transforming growth factor alpha expression as a potential survival prognosticator in patients with oesophageal adenocarcinoma receiving high dose radiation and chemotherapy. Int. J. Rad. Oncol. Biol. Phys., 31, 567-569.
44. SCHMID KW, HELPAP B, TOTSCH M, KIRCHMAIR R, DOCKHORN-DWORNICZAK B, BOCKER W AND FISCHER-COLBRIE R. (1994). Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate. Histopathology, 24, 233-239.
45. SCHREIBER AB, WINKLER ME AND DERYNCK R. (1986). Transforming growth factor α: a more potent angiogenic mediator than epidermal growth factor. Science, 232, 1250-1253.
46. SCHUURMANS AL, BOLT J, VELDSCHOLTE J AND MULDER E. (1991). Regulation of the growth of LNCaP tumor cells by growth factors and steroid hormones. J. Steroid Biochem. Mol. Biol., 40, 193-197.
47. TAKAHASHI A, SASAKI H, KIM SJ, TOBISU K, KAKIZOE T, TSUKAMOTO T, KUMAMOTO Y, SUGIMURA T AND TERADA M. (1994). Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res., 54, 4233-4237.
48. TOI M, HOSHINA S, TAKAYANAGI T AND TOMINAGA T. (1994). Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res., 85, 1045-1049.
49. TOI M, KONDO S, SUZUKI H, YAMAMOTO Y, INADA K, IMAMAWA T, TANIGUCHI T AND TOMINAGA T. (1996). Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer, 77, 1101-1106.
50. TURBAT-HERRERA EA, HERRERA GA, GORE I, LOTT RL, GRIZZLE WE AND BONNIN JM. (1988). Neuroendocrine differentiation in prostatic carcinoma. A retrospective autopsy study. Arch. Pathol. Lab. Med., 112, 1100-1105.
51. VESALAINEN S, LIPPONEN P, TALJA M, ALHAVA E AND SYRJANEN K. (1994). Tumor vascularity and basement membrane structure as prognostic factors in T12MO prostatic adenocarcinoma. Anticancer Res., 14, 709-714.
52. VUKANOVIC J, HARTLEY-ASP B AND ISAACS JT. (1995). Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancer. Prostate, 26, 235-246.
53. WAKUI S, FURUSATO M, ITOH T, SASAKI H, AKIYAMA A, KINOSHITA I, ASANO K, TOKUDA T, AIZAWA S AND USHIGOME S. (1992). Tumour angiogenesis in prostatic carcinoma with and without bone metastasis: a morphological study. J. Pathol., 168, 257-262.
54. WEIDNER N, FOLKMAN J, POZZA F, BEVILACQUA P, ALLRED EN, MOORE DH, MELI S AND GASPARINI G. (1992). Tumor angiogenesis. A new significant and independent prognostic-indicator in early stage breast carcinoma. J. Natl Cancer Inst., 84, 1875-1887.
55. WEIDNER N, CARROLL PR, FLAX J, BLUMENFELD W AND FOLKMAN J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol., 143, 401-409.
56. WEINDEL K, MORINGLANE JR, MARME D AND WEICH HA. (1994). Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: key to angiogenesis. Neurosurgery, 35, 439- 449.
57. YAMAMOTO T, TERADA N, NISHIZAWA Y AND PETROW V. (1994) Angiostatic activities of medroxyprogesterone acetate and its analogues. Int. J. Cancer, 56, 393-399.
58. YAMAZAKI K, ABE S, TAKEKAWA H, SUKOH N, WATANABE N, OGURA S, NAKAJIMA I, ISOBE H, INOUE K AND KAWAKAMI Y. (1994). Tumor angiogenesis in human lung adenocarcinoma. Cancer, 74, 2245-2250.
59. ZAGZAG D. (1995). Angiogenic growth factors in neural embryogenesis and neoplasia. Am. J. Pathol., 146, 293-309.